A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation

In the open prospective non-randomized single-center study we recruited patients with advanced NSCLC harboring EGFR mutations. Initially there were two months of treatment by gefitinib 250 mg daily. Then, after a 2-week drug-free period, 3 cycles of paclitaxel 175 mg / m2 and carboplatin AUC5 were a...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: K. K. Laktionov, D. I. Yudin, V. V. Breder, E. V. Reutova, K. P. Laktionov, D. T. Marinov, D. A. Peregudov, M. S. Ardzinba
Aineistotyyppi: Artigo
Kieli:Russo
Julkaistu: Remedium Group LLC 2019-06-01
Sarja:Медицинский совет
Aiheet:
nsclc
egfr
tyrosine kinase inhibitors
integrated chemotherapy
Linkit:https://www.med-sovet.pro/jour/article/view/3060
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia